We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Treatment Program for Anemia in AIDS Patients

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00002022
First Posted: August 31, 2001
Last Update Posted: December 9, 2005
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
NIH AIDS Clinical Trials Information Service
November 2, 1999
August 31, 2001
December 9, 2005
Not Provided
Not Provided
Not Provided
Not Provided
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Treatment Program for Anemia in AIDS Patients
Treatment Program for Anemia in AIDS Patients
The objective of the Eprex (erythropoietin) Treatment Program is to provide erythropoietin for the treatment of anemia in AIDS patients.
Not Provided
Interventional
Not Provided
Primary Purpose: Treatment
  • HIV Infections
  • Cytopenias
Drug: Epoetin alfa
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
Not Provided
Not Provided

Exclusion Criteria

Co-existing Condition:

Patients with the following are excluded:

  • Life expectancy < 3 months.
  • = or < grade 4 performance score.
  • AIDS-related dementia.
  • Uncontrolled hypertension.
  • Acute symptomatic opportunistic infection or other AIDS-defining illness.

Patients with the following are excluded:

  • Life expectancy < 3 months.
  • = or < grade 4 performance score.
  • AIDS-related dementia.
  • Uncontrolled hypertension.
  • Acute symptomatic opportunistic infection or other AIDS-defining illness.

Patients must have:

  • A clinical diagnosis of AIDS.
  • Hematocrit < 30 percent.
  • Endogenous serum erythropoietin level = or < 500 U/ml.
  • A life expectancy = or > 3 months.
  • > Grade 4 performance score.
Sexes Eligible for Study: All
12 Years and older   (Child, Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00002022
004G
I88-083
Not Provided
Not Provided
Not Provided
Not Provided
R W Johnson Pharmaceutical Research Institute
Not Provided
Not Provided
NIH AIDS Clinical Trials Information Service
February 1991

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP